mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
== Assays == Several assays were developed to monitor the activity of polyphenol oxidases and to evaluate the inhibition potency of polyphenol oxidase inhibitors. In particular, ultraviolet/visible (UV/Vis) spectrophotometry-based assays are widely applied. The most common UV/Vis spectrophotometry assay involves the monitoring of the formation of o-quinones, which are the products of polyphenol oxidase-catalysed reactions, or the consumption of the substrate. Alternative spectrophotometric method that involves the coupling of o-quinones with nucleophilic reagents such as 3-methyl-2-benzothiazolinonehydrazone hydrochloride (MBTH) was also used. Other techniques, such as activity staining assays with the use of polyacrylamide gel electrophoresis, tritium-based radioactive assays, oxygen consumption assay, and nuclear magnetic resonance (NMR)–based assay were also reported and used.
==== Covalently linked gels ==== Three-dimensional covalently linked polymer networks are insoluble in all solvents, they merely swell in good solvents. Thermoresponsive polymer gels show a discontinuous change of the degree of swelling with temperature. At the volume phase transition temperature (VPTT) the degree of swelling changes drastically. Researchers try to exploit this behavior for temperature-induced drug delivery. In the swollen state, previously incorporated drugs are released easily by diffusion. More sophisticated "catch and release" techniques have been elaborated in combination with lithography and molecular imprinting.
=== Misfolded and sugar degrons === In addition to recognizing amino acids, ubiquitin ligases can also detect unusual features on substrates that serve as signals for their destruction. For example, San1 (Sir antagonist 1), a nuclear protein quality control in yeast, has a disordered substrate binding domain, which allows it to bind to hydrophobic domains of misfolded proteins. Misfolded or excess unassembled glycoproteins of the ERAD pathway, on the other hand, are recognized by Fbs1 and Fbs2, mammalian F-box proteins of E3 ligases SCFFbs1and SCFFbs2. These recognition domains have small hydrophobic pockets allowing them to bind high-mannose containing glycans.
Beginning with his January 29, 2002 State of the Union address, Bush began publicly focusing attention on Iraq, which he labeled as part of an "axis of evil" allied with terrorists and posing "a grave and growing danger" to U.S. interests through possession of weapons of mass destruction. In the latter half of 2002, CIA reports contained assertions of Saddam Hussein's intent of reconstituting nuclear weapons programs, not properly accounting for Iraqi biological and chemical weapons, and that some Iraqi missiles had a range greater than allowed by the UN sanctions. Contentions that the Bush Administration manipulated or exaggerated the threat and evidence of Iraq's weapons of mass destruction capabilities would eventually become a major point of criticism for the president. In late 2002 and early 2003, Bush urged the United Nations to enforce Iraqi disarmament mandates, precipitating a diplomatic crisis. In November 2002, Hans Blix and Mohamed ElBaradei led UN weapons inspectors in Iraq, but were advised by the U.S. to depart the country four days prior to the U.S. invasion, despite their requests for more time to complete their tasks. The U.S. initially sought a UN Security Council resolution authorizing the use of military force but dropped the bid for UN approval due to vigorous opposition from several countries. The Bush administration's claim that the Iraq War was part of the war on terror had been questioned and contested by political analysts.
Acitretin, sold under the brand names Neotigason and Soriatane, is a second-generation retinoid. It is taken orally, and is typically used for psoriasis. It was patented in Germany in 1974 and approved for medical use in the United States in 1996. Acitretin is an oral retinoid used in the treatment of severe resistant psoriasis. Because of the potential for problems and severe side effects it is generally used in only very severe cases of psoriasis that have been unresponsive to other treatments. It binds to nuclear receptors that regulates gene transcription. They induce keratinocyte differentiation and reduce epidermal hyperplasia, leading to the slowing of cell reproduction. Acitretin is readily absorbed and widely distributed after oral administration. A therapeutic effect occurs after two to four weeks or longer. Patients who have received the medication are advised against giving blood for at least three years due to the risk of birth defects.
Sources: en.wikipedia.org
Darryl Kile, a former teammate with the Astros, died of a heart attack on June 22, 2002, while an active player for the Cardinals, before a game against the Cubs. The Darryl Kile Good Guy Award was established in his honor, annually for one player on both the Cardinals and the Astros. Bagwell was the first recipient for the Astros in 2003. Ken Caminiti, another former teammate of Bagwell's, died on October 10, 2004. Bagwell delivered a eulogy at his funeral. Bagwell is a recovering alcoholic. He struggled with addiction for several years until 2017.
== Early life and education == Sangeeta Bhatia was born in 1968 in Boston, Massachusetts, to parents who emigrated from India. She is an alumna of Lexington High School in Lexington, MA. Her father was an engineer and entrepreneur, and her mother was one of the first women to receive an MBA in India. Bhatia's interest in engineering was sparked during her 10th-grade biology class and a visit with her father to an MIT lab, where she witnessed a demonstration of an ultrasound machine for cancer treatment. She pursued bioengineering at Brown University, where her involvement in a research group studying artificial organs solidified her decision to pursue graduate studies in the field. After graduating with honors in 1990, Bhatia was initially rejected from the MD-PhD program run by the Harvard-MIT Division of Health Sciences and Technology (HST) but was accepted into the Mechanical Engineering Master's program. She was subsequently accepted into the HST MD-PhD program, where she was advised by Mehmet Toner. She received her Ph.D. in 1997 and her M.D. in 1999, followed by postdoctoral training at Massachusetts General Hospital. Bhatia met her husband, Jagesh Shah, as classmates in HST. Shah is currently an executive in the biotechnology industry. They have two daughters.
=== Blood test === see also: blood doping The blood test detects illegal performance enhancement drugs through the measurement of indicators that change with the use of recombinant human erythropoietin:
This property is what gives DNA its semi-conservative nature where one strand of new DNA is from an original parent strand. Although the structure of DNA showed how inheritance works, it was still not known how DNA influences the behavior of cells. In the following years, scientists tried to understand how DNA controls the process of protein production. It was discovered that the cell uses DNA as a template to create matching messenger RNA, molecules with nucleotides very similar to DNA. The nucleotide sequence of a messenger RNA is used to create an amino acid sequence in protein; this translation between nucleotide sequences and amino acid sequences is known as the genetic code. With the newfound molecular understanding of inheritance came an explosion of research. A notable theory arose from Tomoko Ohta in 1973 with her amendment to the neutral theory of molecular evolution through publishing the nearly neutral theory of molecular evolution. In this theory, Ohta stressed the importance of natural selection and the environment to the rate at which genetic evolution occurs. One important development was chain-termination DNA sequencing in 1977 by Frederick Sanger. This technology allows scientists to read the nucleotide sequence of a DNA molecule. In 1983, Kary Banks Mullis developed the polymerase chain reaction, providing a quick way to isolate and amplify a specific section of DNA from a mixture. The efforts of the Human Genome Project, Department of Energy, NIH, and parallel private efforts by Celera Genomics led to the sequencing of the human genome in 2003.
The total ion current chromatogram (TICC) represents the summed intensity across the entire range of masses being detected at every point in the analysis. The range is typically several hundred mass-to-charge units or more. In complex samples, the TICC often provides limited information as multiple analytes elute simultaneously, obscuring individual species.
Sources: en.wikipedia.org
Since most of the dissolved CO2 remains as CO2 molecules, Ka1(apparent) has a much larger denominator and a much smaller value than the true Ka1. The bicarbonate ion is an amphoteric species that can act as an acid or as a base, depending on pH of the solution. At high pH, it dissociates significantly into the carbonate ion (CO32–):
Gestational diabetes is a condition in which an individual without diabetes develops high blood sugar levels during pregnancy. Gestational diabetes generally results in few symptoms. Obesity increases the rate of pre-eclampsia, cesarean sections, and embryo macrosomia, as well as gestational diabetes. Babies born to individuals with poorly treated gestational diabetes are at increased risk of macrosomia, of having hypoglycemia after birth, and of jaundice. If untreated, diabetes can also result in stillbirth. Long term, children are at higher risk of being overweight and of developing type 2 diabetes. Gestational diabetes can occur during pregnancy because of insulin resistance or reduced production of insulin. Risk factors include being overweight, previously having gestational diabetes, a family history of type 2 diabetes, and having polycystic ovarian syndrome. Diagnosis is by blood tests. For those at normal risk, screening is recommended between 24 and 28 weeks' gestation. For those at high risk, testing may occur at the first prenatal visit. Maintaining a healthy weight and exercising before pregnancy assists in prevention. Gestational diabetes is treated with a healthy eating plan, exercise, medication (such as metformin), and sometimes insulin injections. Most people manage blood sugar with diet and exercise. Blood sugar testing among those affected is often recommended four times daily. Breastfeeding is recommended as soon as possible after birth. Gestational diabetes affects 3–9% of pregnancies, depending on the population studied.
Straub continued to work on actin, and in 1950 reported that actin contains bound ATP and that, during polymerization of the protein into microfilaments, the nucleotide is hydrolyzed to ADP and inorganic phosphate (which remain bound to the microfilament). Straub suggested that the transformation of ATP-bound actin to ADP-bound actin played a role in muscular contraction. In fact, this is true only in smooth muscle, and was not supported through experimentation until 2001. The amino acid sequencing of actin was completed by M. Elzinga and co-workers in 1973. The crystal structure of G-actin was solved in 1990 by Kabsch and colleagues. In the same year, a model for F-actin was proposed by Holmes and colleagues following experiments using co-crystallization with different proteins. The procedure of co-crystallization with different proteins was used repeatedly during the following years, until in 2001 the isolated protein was crystallized along with ADP. However, there is still no high-resolution X-ray structure of F-actin. The crystallization of G-actin was possible due to the use of a rhodamine conjugate that impedes polymerization by blocking the amino acid cys-374. Christine Oriol-Audit died in the same year that actin was first crystallized but she was the researcher that in 1977 first crystallized actin in the absence of Actin Binding Proteins (ABPs). However, the resulting crystals were too small for the available technology of the time.
== Theory == The interpretation of scattering measurements made at the multiangular locations relies upon some knowledge of the a priori properties of the particles or molecules measured. The scattering characteristics of different classes of such scatterers may be interpreted best by application of an appropriate theory. For example, the following theories are most often applied. Rayleigh scattering is the simplest and describes elastic scattering of light or other electromagnetic radiation by objects much smaller than the incident wavelength. This type of scattering is responsible for the blue color of the sky during the day and is inversely proportional to the fourth power of wavelength. The Rayleigh–Gans approximation is a means of interpreting MALS measurements with the assumption that the scattering particles have a refractive index, n1, very close to the refractive index of the surrounding medium, n0. If we set m = n1/n0 and assume that |m - 1| << 1, then such particles may be considered as composed of very small elements, each of which may be represented as a Rayleigh-scattering particle. Thus each small element of the larger particle is assumed to scatter independently of any other. Lorenz–Mie theory is used to interpret the scattering of light by homogeneous spherical particles. The Rayleigh–Gans approximation and the Lorenz–Mie theory produce identical results for homogeneous spheres in the limit as |1 − m| → 0. Lorenz–Mie theory may be generalized to spherically symmetric particles per reference. More general shapes and structures have been treated by Erma.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.